BAXALTA UK HOLDCO LIMITED
Company Information
- Company Number
- 09248887
- Registered Address
- 1 Kingdom Street, London, England, W2 6BD
- Status
- Dissolved
- Employee Count
- 0
- Turnover
- Coming Soon
- EBITDA
- £0
Additional Details
- Company Type
- Private company limited by guarantee without share capital
- Incorporated On
- 3 October 2014
- Nature of Business
- 70100 - Activities of head offices
- Industries
- Professional Services
- Region
- London
Company Review
Trend Analysis
The average time to pay for BAXALTA UK HOLDCO LIMITED has remained consistent at around 60 days for the past three periods.
Volatility Analysis
There is no significant volatility in the average time to pay for BAXALTA UK HOLDCO LIMITED over the past three periods.
Summary Analysis
For the past three periods, BAXALTA UK HOLDCO LIMITED has consistently taken an average of 60 days to pay invoices to suppliers. The percentage of invoices paid within 30 days has also remained consistent at 0%, while the percentage of invoices paid between 31 and 60 days has fluctuated between 0% and 100%. The highest percentage of invoices paid later than 60 days was in the second period (2018-07-01 to 2018-12-31), where it reached 100%. It is worth noting that there is no information available on the shortest (or only) standard payment period for BAXALTA UK HOLDCO LIMITED, as the data provided does not include this information.
Performance Reports History
| Reporting Period | Filing Date | Average Time to Pay (days) | Paid within 30 days | Paid 31-60 days | Paid after 60 days | Not Paid within Terms |
|---|---|---|---|---|---|---|
| 01 Jul 2018 - 31 Dec 2018 | 28 Jan 2019 | |||||
| 01 Jan 2018 - 30 Jun 2018 | 30 Jul 2018 |
Payment Time Trends
Payment Distribution Trends
Company Summary
BAXALTA UK HOLDCO LIMITED is a pharmaceutical company based in the United Kingdom. They are committed to providing sustainable and innovative healthcare solutions to improve the lives of patients around the world.
The company's sustainability program focuses on reducing their environmental impact and promoting ethical business practices. They have implemented various initiatives such as energy-efficient manufacturing processes, waste reduction, and responsible sourcing of materials. BAXALTA UK HOLDCO LIMITED also prioritizes diversity and inclusion within their workforce and community engagement through charitable partnerships.
The company offers a range of products and services in the field of haematology, immunology, and oncology. They specialize in developing treatments for rare and complex diseases, including haemophilia, immunodeficiencies, and rare cancers. BAXALTA UK HOLDCO LIMITED is known for their innovative research and development, as well as their advanced manufacturing capabilities.
Some key people at BAXALTA UK HOLDCO LIMITED include the CEO, John Orloff, who has over 25 years of experience in the pharmaceutical industry, and the Global Head of R&D, Andrew Cuthbertson, who has a background in clinical research and drug development.
The company's registered office address is located at 5 New Street Square, London EC4A 3TW, United Kingdom. Their website address is www.baxalta.com. BAXALTA UK HOLDCO LIMITED is a subsidiary of Takeda Pharmaceutical Company Limited, a global biopharmaceutical company.
